Skip to content

Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time

May 14, 2026 · 2 h 8 min

Show notes

Keytruda is Merck's $31 billion a year PD-1 inhibitor and the best-selling cancer drug of all time. In Episode 3 of Approved, Alex Kesin and Matthew Pech trace the development of pembrolizumab , featuring interviews the scientists who drove the program forward : co-inventors Gregory Carven and Michel Streuli, and former Merck oncology CMO Roy Baynes.

Topics include preclinical PD1 / CTLA-4 checkpoint biology that brought industry attention to the target (Jim Allison's CTLA-4 work and Tasuku Honjo's PD-1 discovery); how pembro started as a failed rheumatoid arthritis antibody program at a Dutch subsidiary of a paint company; the two mega-mergers that nearly killed the program; the biomarker enrichment trial design behind KEYNOTE-024 that let Merck break BMS's lead in lung cancer; the 41-patient Johns Hopkins MSI-H trial behind the first tissue-agnostic FDA approval, and the Jimmy Carter melanoma case that brought pembrolizumab to the public conscious. The episode closes on what comes next for Merck: the 2028 patent cliff, the Keytruda QLEX subcutaneous launch, and efforts to find the next blockbuster checkpoint inhibitor, including Summit/Akeso's PD-1 / VEGF bispecific ivonescimab.


CHAPTERS


00:00:00 — Introduction: The Best-Selling Cancer Drug of All Time


00:02:15 — Part One — A Century of Failed Cancer Immunotherapy


00:04:17 — T Cells, CD28, and the Two-Signal Model of Immune Activation


00:06:25 — Jim Allison's CTLA-4 Discovery and the Path to Yervoy


00:12:03 — Tasuku Honjo Discovers PD-1: A Better Brake on T Cells


00:14:26 — Lieping Chen and the PD-L1 Tumor Evasion Hypothesis


00:16:26 — Part Two — Organon: The Dutch Paint-Company Subsidiary Behind Keytruda


00:19:48 — How Michel Streuli Caught the Solid-Phase Screening Artifact


00:22:09 — The Accidental Antagonist: From Rheumatoid Arthritis Drug to Cancer Drug


00:26:34 — Sponsor: Grant Detmer (JLL) on Biotech Real Estate Strategy


00:30:01 — Russian Nesting-Doll M&A: Schering-Plough Acquires Organon (2007)


00:31:43 — The $41 Billion Merck–Schering-Plough Mega-Merger of 2009


00:34:58 — Corporate Guerrilla Warfare: Four Scrappy Stunts That Saved Pembrolizumab


00:39:32 — BioNovion's Spite-Company Bid to Buy Pembro Back


00:42:10 — BMS at ASCO 2010: The Data Print That Revived Merck's PD-1 Program


00:45:55 — Part Three — Roger Perlmutter Joins a Bleeding Merck (April 2013)


00:50:48 — "Let Me Manage the Tigers": Ken Frazier Backs the All-In Bet on Pembrolizumab


00:55:22 — Breakthrough Therapy Designation and Eric Rubin's Adaptive Trial Design


00:58:25 — Keytruda's 2014 FDA Approval Erases BMS's Four-Year Lead


01:00:24 — The Lung Cancer Battlefield and the PD-L1 Biomarker Bet


01:02:19 — BMS vs. Merck: All-Comers vs. Biomarker-Enriched Trial Strategy


01:08:18 — KEYNOTE-024 vs. CheckMate-026: The Trial That Decided the Category


01:12:03 — Luis Diaz, MSI-H, and the Failed BMS Trial That Made Keytruda Tissue-Agnostic


01:17:18 — KEYNOTE-189: Perlmutter's Bet on Combining Keytruda with Chemotherapy


01:19:21 — Merck's Clinical Development Playbook: Basket Trials, Backwards March, External Collabs


01:25:29 — Part Four — The IO Graveyard: TIGIT, CD47, IDO1, LAG-3 and Tens of Billions Incinerated


01:30:23 — Why PD-1 Was the Only Checkpoint That Worked (Lieping Chen Revisited)


01:33:32 — Part Five — Inside the Best-Selling Drug of All Time


01:37:03 — "Build a Wall, High and Wide": Merck’s Commercial Strategy for Keytruda


01:43:44 — Part Six — The Patent Cliff and Loss of Exclusivity in Pharma


01:45:35 — Keytruda QLEX (Subcutaneous) and the Lifecycle Management Playbook


01:50:23 — PD-1/VEGF Bispecifics: Ivonescimab, Summit Therapeutics, and the Next Threat


01:55:31 — The Scorecard: Patient, Academic, and Financial Impact


02:01:19 — Who Actually Profited: Merck vs. Organon vs. the Scientists Who Built the Drug


02:05:54 — Epilogue: The Jimmy Carter Drug

Sources

Last updated: May 2026


Essential reading


Primary interviews

Greg Carven, Michel Streuli, Roy Baynes — Approved podcast interviews (2026). Quotes attributed to these speakers come from these conversations unless otherwise noted.


Foundational science


Pivotal trials

All episodes of Approved

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.